Intervention strategies for emerging viruses: Use of antivirals

Current Opinion in Virology

Volumn 3, Issue 2, 2013, Pages 217-224

  Debing, Yannick ^a   Jochmans, Dirk ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AG 7404; ALPHA INTERFERON; ANTIVIRUS AGENT; BTA C286; BTAC 286; CASTANOSPERMINE 6 BUTYRATE; CHLOROQUINE; ENVIROXIME; FAVIPIRAVIR; FGI 103; FGI 104; FGI 106; MDT 637; MRL 1327; NSC 62914; PLACEBO; PLECONARIL; RECOMBINANT VACCINE; RIBAVIRIN; ST 193; T 00127 HEV1; T 1106; TBZE 029; TMC 353121; TTP 8307; UNCLASSIFIED DRUG; VAPENDAVIR;

ANTIVIRAL ACTIVITY; ARENAVIRUS; ARENAVIRUS INFECTION; ARTICLE; BUNYAVIRUS; BUNYAVIRUS INFECTION; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; COMMON COLD; COMPLEX FORMATION; CRIMEAN CONGO HEMORRHAGIC FEVER; DENGUE; DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; ENTEROVIRUS 71; ENTEROVIRUS INFECTION; FILOVIRUS; FILOVIRUS INFECTION; GASTROINTESTINAL SYMPTOM; GLYCOSYLATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS E; HEPATITIS E VIRUS; HERPES VIRUS; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA VIRUS; JAPANESE ENCEPHALITIS VIRUS; LASSA FEVER; LASSA VIRUS; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RHABDOVIRUS INFECTION; RHINOVIRUS INFECTION; RIFT VALLEY FEVER; SARS CORONAVIRUS; SEPSIS; VIRUS REPLICATION; VIRUS SHEDDING; WEST NILE FLAVIVIRUS; YELLOW FEVER FLAVIVIRUS;

EID: 84880056374     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.03.001     Document Type: Review

References (93)

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA: Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012, 367:1814-1820.
2. World Health Organization: Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control - New Edition. WHO Press; 2009.
3. Simmons CP, Wolbers M, Nguyen MN, Whitehorn J, Shi PY, Young P, Petric R, Nguyen VV, Farrar J, Wills B: Therapeutics for dengue: recommendations for design and conduct of early-phase clinical trials. PLoS Negl Trop Dis 2012, 6:e1752.
4. Julander JG: Experimental therapies for yellow fever. Antiviral Res 2013, 97:169-179.
5. Delang L, Coelmont L, Neyts J: Antiviral therapy for hepatitis C virus: beyond the standard of care. Viruses 2010, 2:826-866.
6. Noble CG, Seh CC, Chao AT, Shi PY: Ligand-bound structures of the dengue virus protease reveal the active conformation. J Virol 2012, 86:438-446.
7. Noble CG, Shi PY: Structural biology of dengue virus enzymes: towards rational design of therapeutics. Antiviral Res 2012, 96:115-126.
8. Delang L, Neyts J, Vliegen I, Abrignani S, Neddermann P, De Francesco R: HCV-specific directly acting antiviral drugs. Curr Top Microbiol Immunol 2013, 369:289-320.
9. Lin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A et al.: An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A 2009, 106:20435-20439.
10. Chen YL, Yin Z, Duraiswamy J, Schul W, Lim CC, Liu B, Xu HY, Qing M, Yip A, Wang G et al.: Inhibition of dengue virus RNA synthesis by an adenosine nucleoside. Antimicrob Agents Chemother 2010, 54:2932-2939.
11. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh HL, Farrar J, Nguyen QT, Tran HT, Nguyen CV, Merson L et al.: A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 2012, in press.
12. Zou G, Chen YL, Dong H, Lim CC, Yap LJ, Yau YH, Shochat SG, Lescar J, Shi PY: Functional analysis of two cavities in flavivirus NS5 polymerase. J Biol Chem 2011, 286:14362-14372.
13. Lim SP, Sonntag LS, Noble C, Nilar SH, Ng RH, Zou G, Monaghan P, Chung KY, Dong H, Liu B et al.: Small molecule inhibitors that selectively block dengue virus methyltransferase. J Biol Chem 2011, 286:6233-6240.
14. Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, Shi PY: Inhibition of dengue virus by targeting viral NS4B protein. J Virol 2011, 85:11183-11195.
15. Patkar CG, Larsen M, Owston M, Smith JL, Kuhn RJ: Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay. Antimicrob Agents Chemother 2009, 53:4103-4114.
16. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, Zhou J, Poh MK, Florez de Sessions P, Niyomrattanakit P et al.: Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 2011, 85:6548-6556.
17. Watanabe S, Rathore AP, Sung C, Lu F, Khoo YM, Connolly J, Low J, Ooi EE, Lee HS, Vasudevan SG: Dose- and scheduledependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res 2012, 96:32-35.
18. Collett MS, Neyts J, Modlin JF: A case for developing antiviral drugs against polio. Antiviral Res 2008, 79:179-187.
19. McMinn PC: Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol 2012, 2:199-205.
20. Thibaut HJ, De Palma AM, Neyts J: Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol 2012, 83:185-192.
21. Senior K: FDA panel rejects common cold treatment. Lancet Infect Dis 2002, 2:264.
22. Kouiavskaia DV, Dragunsky EM, Liu HM, Oberste MS, Collett MS, Chumakov KM: Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073. Antivir Ther 2011, 16:999-1004.
23. Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, Tran JQ: In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. Antimicrob Agents Chemother 2005, 49:2267-2275.
24. Patick AK: Rhinovirus chemotherapy. Antiviral Res 2006, 71:391-396.
25. Tan J, George S, Kusov Y, Perbandt M, Anemüller S, Mesters JR, Norder H, Coutard B, Lacroix C, Leyssen P et al.: 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol 2013, in press.
26. Shimizu H, Agoh M, Agoh Y, Yoshida H, Yoshii K, Yoneyama T, Hagiwara A, Miyamura T: Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J Virol 2000, 74:4146-4154.
27. De Palma AM, Pürstinger G, Wimmer E, Patick AK, Andries K, Rombaut B, De Clercq E, Neyts J: Potential use of antiviral agents in polio eradication. Emerg Infect Dis 2008, 14:545-551.
28. van der Schaar HM, van der Linden L, Lanke KH, Strating JR, Pürstinger G, de Vries E, de Haan CA, Neyts J, van Kuppeveld FJ: Coxsackievirus mutants that can bypass host factor PI4KIIIb and the need for high levels of PI4P lipids for replication. Cell Res 2012, 22:1576-1592.
29. De Palma AM, Thibaut HJ, van der Linden L, Lanke K, Heggermont W, Ireland S, Andrews R, Arimilli M, Al-Tel TH, De Clercq E et al.: Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother 2009, 53:1850-1857.
30. Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H: Phosphatidylinositol 4-kinase III beta is a target of enviroximelike compounds for antipoliovirus activity. J Virol 2011, 85:2364-2372.
31. Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER, Srivastava S: Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother 1985, 27:102-106.
32. Solignat M, Gay B, Higgs S, Briant L, Devaux C: Replication cycle of chikungunya: a re-emerging arbovirus. Virology 2009, 393:183-197.
33. Delogu I, de Lamballerie X: Chikungunya disease and chloroquine treatment. J Med Virol 2011, 83:1058-1059.
34. Bourjot M, Leyssen P, Eydoux C, Guillemot JC, Canard B, Rasoanaivo P, Guéritte F, Litaudan M: Chemical constituents of Anacolosa pervilleana and their antiviral activities. Fitoterapia 2012, 83:1076-1080.
35. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, Ahola T, Tammela P: Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS ONE 2011, 6:e28923.
36. Bourjot M, Delang L, Nguyen VH, Neyts J, Guéritte F, Leyssen P, Litaudon M: Prostratin and 12-O-tetradecanoylphorbol 13-acetate are potent and selective inhibitors of Chikungunya virus replication. J Nat Prod 2012, 75:2183-2187.
37. Delogu I, Pastorino B, Baronti C, Nougairède A, Bonnet E, de Lamballerie X: In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Antiviral Res 2011, 90:99-107.
38. Bassetto M, De Burghgraeve T, Delang L, Massarotti A, Coluccia A, Zonta N, Gatti V, Colombano G, Sorba G, Romano S et al.: Computer-aided identification, design and synthesis of a novel series of compounds with selective antiviral activity against chikungunya virus. Antiviral Res 2013, 98:12-18.
39. Yang S, Chen SJ, Hsu MF, Wu JD, Tseng CT, Liu YF, Chen HC, Kuo CW, Wu CS, Chang LW et al.: Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J Med Chem 2006, 49:4971-4980.
40. Ratia K, Pegan S, Takayama J, Sleeman K, Coughlin M, Baliji S, Chaudhuri R, Fu W, Prabhakar BS, Johnson ME et al.: A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A 2008, 105:16119-16124.
41. Ghosh AK, Takayama J, Rao KV, Ratia K, Chaudhuri R, Mulhearn DC, Lee H, Nichols DB, Baliji S, Baker SC et al.: Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation. J Med Chem 2010, 53: 4968-4979.
42. Jacobs J, Grum-Tokars V, Zhou Y, Turlington M, Saldanha SA, Chase P, Eggler A, Dawson ES, Baez-Santos YM, Tomar S et al.: Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2- (pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. J Med Chem 2013, 56:534-546.
43. Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP, Groutas WC, Chang KO: Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol 2012, 86:11754-11762.
44. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S: Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol 2012, 86:6537-6545.
45. Tanner JA, Zheng BJ, Zhou J, Watt RM, Jiang JQ, Wong KL, Lin YP, Lu LY, He ML, Kung HF et al.: The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol 2005, 12:303-311.
46. Yang N, Tanner JA, Zheng BJ, Watt RM, He ML, Lu LY, Jiang JQ, Shum KT, Lin YP, Wong KL et al.: Bismuth complexes inhibit the SARS coronavirus. Angew Chem Int Ed Engl 2007, 46:6464-6468.
47. Adedeji AO, Singh K, Calcaterra NE, DeDiego ML, Enjuanes L, Weiss S, Sarafianos SG: Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrob Agents Chemother 2012, 56:4718-4728.
48. Aggarwal R: Clinical presentation of hepatitis E. Virus Res 2011, 161:15-22.
49. Meng XJ: From barnyard to food table: the omnipresence of hepatitis E virus and risk for zoonotic infection and food safety. Virus Res 2011, 161:23-30.
50. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, Wang H, Yang CL, Jiang HM, Cai JP et al.: Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomized, double-blind placebo-controlled, phase 3 trial. Lancet 2010, 376:895-902.
51. Rein DB, Stevens G, Theaker J, Wittenborn JS, Wiersma ST: The global burden of hepatitis E virus. Hepatology 2011, 55:988-997.
52. Kamar N, Garrouste C, Haagsma EB, Garrigue V, Pischke S, Chauvet C, Dumortier J, Cannesson A, Cassuto-Viguier E, Thervet E et al.: Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011, 140:1481-1489.
53. Mallet V, Nicand E, Sultanik P, Chakvetadze C, Tessé S, Thervet E, Mouthon L, Sogni P, Pol S: Brief communication: case reports of ribavirin treatment for chronic hepatitis E. Ann Intern Med 2010, 153:85-89.
54. Kamar N, Rostaing L, Abravanel F, Garrouste C, Lhomme S, Esposito L, Basse G, Cointault O, Ribes D, Nogier MB, Alric L, Peron JM, Izopet J: Ribavirin therapy inhibits viral replication on patients with chronic hepatitis E virus infection. Gastroenterology 2010, 139:1612-1618.
55. Chaillon A, Sirinelli A, De Muret A, Nicand E, d'Alteroche L, Goudeau A: Sustained virologic response with ribavirin in chronic hepatitis E virus infection in heart transplantation. J Heart Lung Transplant 2011, 30:841-843.
56. Pischke S, Stiefel P, Franz B, Bremer B, Suneetha PV, Heim A, Ganzenmueller T, Schlue J, Horn-Wichmann R, Raupach R et al.: Chronic hepatitis E in heart transplant recipients. Am J Transplant 2012, 12:3128-3133.
57. Kamar N, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau-Desangles I, Mansuy JM, Selves J, Peron JM, Otal P, Muscari F, Izopet J: Pegylated interferon-alpha for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis 2010, 50:e30-e33.
58. Dalton HR, Keane FE, Bendail R, Mathew J, Ijaz S: Treatment of chronic hepatitis E in a patient with HIV infection. Ann Intern Med 2011, 155:479-480.
59. Gerolami R, Borentain P, Raissouni F, Motte A, Solas C, Colson P: Treatment of severe hepatitis E by ribavirin. J Clin Virol 2011, 52:60-62.
60. Okamoto H: Hepatitis E virus cell culture models. Virus Res 2011, 161:65-77.
61. Shukla P, Nguyen HT, Faulk K, Mather K, Torian U, Engle RE, Emerson SU: Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depended on an inserted human gene segment acquired by recombination. J Virol 2012, 86:5697-5707.
62. Roymans D, De Bondt HL, Arnoult E, Geluykens P, Gevers T, Van Ginderen M, Verheyen N, Kim H, Willebrords R, Bonfanti JF et al.: Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptadrepeats of the RSV fusion protein. Proc Natl Acad Sci U S A 2010, 107:308-313.
63. Olszewska W, Ispas G, Schnoeller C, Sawant D, Van de Casteele T, Nauwelaers D, Van Kerckhove B, Roymans D, De Meulder M, Rouan MC et al.: Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J 2011, 38:401-408.
64. Liuzzi M, Mason SW, Cartier M, Lawetz C, McCollum RS, Dansereau N, Bolger G, Lapeyre N, Gaudette Y, Lagacé L et al.: Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNAdependent RNA polymerase. J Virol 2005, 79:13105-13115.
65. World Health Organization: WHO Expert Consultation on Rabies - First Report. WHO Press; 2005.
66. Lockhart BP, Tordo N, Tsiang H: Inhibition of rabies virus transcription in rat cortical neurons with the dissociative anesthetic ketamine. Antimicrob Agents Chemother 1992, 36:1750-1755.
67. Willoughby RE Jr, Tieves KS, Hoffman GM, Ghanayem NS, Amlie-Lefond CM, Schwabe MJ, Chusid MJ, Rupprecht CE: Survival after treatment of rabies with induction of coma. N Engl J Med 2005, 352:2508-2514.
68. Superti F, Seganti L, Panà A, Orsi N: Effect of amantadine on rhabdovirus infection. Drugs Exp Clin Res 1985, 11:69-74.
69. Warrell MJ, White NJ, Looareesuwan S, Phillips RE, Suntharasamai P, Chanthavanich P, Riganti M, Fisher-Hoch SP, Nicholson KG, Manatsathit S: Failure of interferon alfa and ribavirin in rabies encephalitis. Br Med J 1989, 299:830-833.
70. Kureishi A, Xu LZ, Wu H, Stiver HG: Rabies in China: recommendations for control. Bull World Health Organ 1992, 70:443-450.
71. Bussereau F, Picard M, Blancou J, Sureau P: Treatment of rabies in mice and foxes with antiviral compounds. Acta Virol 1988, 32:33-49.
72. Jackson AC: Current and future approaches to the therapy of human rabies. Antiviral Res; 2013, in press.
73. Mendenhall M, Russell A, Smee DF, Hall JO, Skirpstunas R, Furuta Y, Gowen BB: Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic fever. PLos Negl Trop Dis 2011, 5:e1342.
74. Burgeson JR, Moore AL, Boutilier JK, Cerruti NR, Gharaibeh DN, Lovejoy CE, Amberg SM, Hruby DE, Tyavanagimatt SR, Alle RD 3rd, Dai D: SAR analysis of a series of acylthiourea derivatives possessing broad-spectrum antiviral activity. Bioorg Med Chem Lett 2012, 22:4263-4272.
75. Burgeson JR, Moore AL, Gharaibeh DN, Larson RA, Cerruti NR, Amberg SM, Hruby DE, Dai D: Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles. Bioorg Med Chem Lett 2013, 23:750-756.
76. Dai D, Burgeson JR, Gharaibeh DN, Moore AL, Larson RA, Cerruti NR, Amberg SM, Bolken TC, Hruby DE: Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole. Bioorg Med Chem Lett 2013, 23:74-749.
77. Gowen BB, Bray M: Progress in the experimental therapy of severe arenaviral infections. Future Microbiol 2011, 6:1429-1441.
78. Boro L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T et al.: Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002, 287:2391-2405.
79. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, Bailey KW, Furuta Y, Sidwellz RW: In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007, 51:3168-3176.
80. Gowen BB, Wong MH, Jung KH, Smee DF, Morrey JD, Furuta Y: Efficacy of favipiravir (T-705) and T-1106 purazine derivatives in phlebovirus disease models. Antiviral Res 2010, 86:121-127.
81. Tasdelen Fisgin N, Ergonul O, Doganci L, Tulek N: The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis 2009, 28:929-933.
82. Ergonul O: Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 2008, 78:125-131.
83. Ergonul O: Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol 2012, 2:215-220.
84. Weingartl HM, Embury-Hyatt C, Nfon C, Leung A, Smith G, Kobinger G: Transmission of Ebola virus from pigs to nonhuman primates. Sci Rep 2012, 2:811.
85. Smee DF, Bray M, Huggins JW: Intracellular phosphorylation of carbocyclic 3-deazaadenosine, an anti-Ebola virus agent. Antivir Chem Chemother 2011, 12:251-258.
86. Bray M, Driscoll J, Huggins JW: Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res 2000, 45:135-147.
87. Côté M, Misasi J, Ren T, Bruchez A, Lee K, Filone CM, Hensley L, Li Q, Ory D, Chandran K, Cunningham J: Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 2011, 477:344-348.
88. Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, Peet NP, Majgier-Baranowska H, Williams JD, Patel I et al.: Identification of a small-molecule entry inhibitor for filoviruses. J Virol 2011, 85:3106-3119.
89. Yermolina MV, Wang J, Caffrey M, Rong LL, Wardrop DJ: Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry. J Med Chem 2011, 54:765-781.
90. Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, Luo G, Nelson EA, Li L, Huang Z et al.: FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am J Transl Res 2009, 1:87-98.
91. Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, Stavale E, Wang P, Chang S, Tang Q et al.: Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009, 83:245-251.
92. Warren TK, Warfield KL, Wells J, Enterlein S, Smith M, Ruthel G, Yunus AS, Kinch MS, Goldblatt M, Aman MJ, Bavari S: Antiviral activity of a small-molecule inhibitor of filovirus infection. Antimicrob Agents Chemother 2010, 54:2152-2159.
93. Panchal RG, Reid SP, Tran JP, Bergeron AA, Wells J, Kota KP, Aman J, Bavari S: Identification of an antioxidant smallmolecule with broad-spectrum antiviral activity. Antiviral Res 2012, 93:23-29.